Printer Friendly

Omnia Biologics and University of Maryland Bioprocess Scale-Up Facility Cooperate in Providing Biopharmaceutical Processing And Manufacture.

ROCKVILLE, Md. -- Biologics contract manufacturer Omnia Biologics, Inc. (Rockville, MD) and University of Maryland Bioprocess Scale-Up Facility (BSF) (College Park, MD) today announced an agreement to cooperate in providing services for the manufacture of biopharmaceutical products. Omnia Biologics (Omnia) is a contract manufacturer focused on the development of innovative biopharmaceutical platforms and technologies.

"The opportunity to collaborate with the world's premier academic bioprocessing facility is a great asset to our customers." commented Dale VanderPutten, CEO, Omnia Biologics "The combination of the BSF scale-up fermentation and training expertise and Omnia's cGMP processes, class 100 sterile fill-finish, and BSL-3 suites provides a unique resource to biotech and academic investigators and reinforces Maryland as a leader in biotechnology." The BSF is the University of Maryland Biotech Program's modern bioprocessing laboratory dedicated to the development and scale-up of biotechnology products and processes. With more than 678 fermentations conducted since 1998 alone, the BSF has accelerated the R&D of local biotechnology leaders such as Human Genome Sciences, NIH and MedImmune, as well as growing Maryland start-ups such as Martek Biosciences and Digene Corporation.

About Omnia Biologics: (www.omniabiologics.com)

Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 12, 2005
Words:245
Previous Article:Fronteer Expands Gold Potential at Agi Dagi- Intersects 12.37 G/T Gold Over 8.40 Metres.
Next Article:Bearish 54 Bcf Storage Injection Helps Futures Continue Slide, reports NGI.


Related Articles
"BioProcess International" from Informa Life Sciences Group.
Omnia Biologics and AT-GC BioPharm Form a Strategic Manufacturing Alliance.
Omnia Biologics and Intradigm Sign Deal for Nanomedicine Manufacture.
Omnia Biologics and Prolong Sign Production Services Agreement.
Omnia Biologics and Aeras Sign Master Services Agreement.
Omnia Biologics and Potentia Pharmaceuticals Sign Manufacturing Agreement.
Millipore Opens $50 Million Research and Development Center.
SEMBIOSYS SIGNS PACT FOR CANGENE PLANT-PRODUCED INSULIN.
Millipore Becomes First Company to Embed RFID Technology in Filtration Products Used for Biopharmaceutical Manufacturing.
Millipore Advances Disposable Manufacturing Strategy with Introduction of New Disposable Mixing System.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters